Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration.

MLA

Tanaka, Asako, et al. “Short-Term Outcomes of 3 Monthly Intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration.” Clinical Ophthalmology, vol. 18, Feb. 2024, pp. 507–16. EBSCOhost, https://doi.org/10.2147/OPTH.S448507.

APA

Tanaka, A., Hata, M., Tsuchikawa, M., Ueda-Arakawa, N. U.-A., Tamura, H., Miyata, M., Takahashi, A., Kido, A., Muraoka, Y., Miyake, M., Ooto, S., & Tsujikawa, A. (2024). Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 18, 507–516. https://doi.org/10.2147/OPTH.S448507

Chicago

Tanaka, Asako, Masayuki Hata, Memiri Tsuchikawa, Naoko Ueda-Arakawa Ueda-Arakawa, Hiroshi Tamura, Manabu Miyata, Ayako Takahashi, et al. 2024. “Short-Term Outcomes of 3 Monthly Intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration.” Clinical Ophthalmology 18 (February): 507–16. doi:10.2147/OPTH.S448507.